An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease.

ABSTRACT:

Background

Alzheimer's disease is the most frequent age-related dementia, and is currently without treatment. To identify possible targets for early therapeutic intervention we focused on glutamate excitotoxicity, a major early pathogenic factor, and the effects of candesartan, an angiotensin receptor blocker of neuroprotective efficacy in cell cultures and rodent models of Alzheimer's disease. The overall goal of the study was to determine whether gene analysis of drug effects in a primary neuronal culture correlate with alterations in gene expression in Alzheimer's disease, thus providing further preclinical evidence of beneficial therapeutic effects.

Methods

Primary neuronal cultures were treated with candesartan at neuroprotective concentrations followed by excitotoxic g

SUBMITTER: Elkahloun AG 

PROVIDER: S-EPMC4731966 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature